Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody, which is in Phase 2b clinical trial for the treatment of atopic dermatitis; ISB 1302, a HER2 X CD3 beat bispecific antibody that is in Phase 1/2 clinical trial for the treatment of metastatic HER2-positive breast cancer; and ISB 1342, a CD38 X CD3 beat bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma. The company's pre-clinical stage product pipeline comprises ISB 880 for the treatment of anti-inflammatory therapy; ISB 1908 and ISB 1909 T-cell engagers for the treatment of oncology; ISB 1442, an innate immune engager for the treatment of oncology; and GRC 39815, an inhibitor of the retinoid-related orphan receptor gamma for the treatment of chronic obstructive pulmonary disorder. It also offers Ryaltris nasal spray for allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.

Glenmark Pharmaceuticals Limited

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Alkermes plc

Pharma Wisdom provides job updates in the pharmaceutical, life science, and healthcare industries, facilitating recruitment efforts.

Pharma Wisdom

Glenmark Pharmaceuticals focuses on the development and manufacturing of high-quality branded and generic medicines for global markets. The company is engaged in creating centers of excellence in dermatology, oncology, and respiratory therapy.

Metric
Company Name	Glenmark Pharmaceuticals Limited	Alkermes plc	Pharma Wisdom
Symbol	GLENMARK	ALKS
MSH ID	COM:GLENMARKPHARMA	COM:ALKERMES	IN:CO:PHARMAWISDOM
Market	STOCKS	STOCKS	PRIVATE
Sector	Healthcare	Healthcare	Commercial & Professional Services
Industry	Drug Manufacturers - Specialty & Generic	Biotechnology	Healthcare
Country	IN	IE	IN
Stage
Employee Count	15.56K	2.10K
Website	glenmarkpharma.com	alkermes.com	pharmawisdom.co.in
LinkedIn
Founders

Metric
Market Cap	4.61B	3.89B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	1.39B	1.66B
Revenue (LTM)
Revenue (NTM)
Gross Profit	466.30M	1.37B
EBITDA	141.12M	486.73M
Operating Income	72.42M	414.12M
Net Income	-177.29M	355.76M
EPS	-0.63	2.14
Diluted EPS	-0.63	2.10
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.62	0.87
Operating Profit Margin	0.07	0.22
EBITDA Margin	0.10	0.29
Net Profit Margin	-0.06	0.25
Return on Equity	-0.07	0.34
Return on Assets		0.20
Return on Capital Employed	0.10	0.23

COM:GLENMARKPHARMA

Glenmark Pharmaceuticals

Last Close

1,478.20

25/11 09:40

Market Cap

390.66B

Beta: -

Volume Today

654.54K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-284.91	20.48
P/B Ratio	2.68	3.24
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	4.30	3.17
EV Multiple	36.82	16.57

Metric
Days Sales Outstanding	161.17	78.13
Days Payables Outstanding	146.28	94.07
Days Inventory Outstanding	172.88	352.33
Operating Cycle	229.31	441.02
Cash Conversion Cycle	55.48	441.02
Asset Turnover	0.84	0.81

Metric
Operating Cash Flow	-90.32M	401.35M
Free Cash Flow	-198.34M	353.31M
Cash Flow to Debt	0.83	1.50
Operating Cash Flow/Sales	0.07	0.29
Free Cash Flow Yield	0.00	0.06

Metric
Cash & Equivalents	195.92M	457.47M
Accounts Receivable	114.46M	-44.51M
Inventory	296.69M	186.41M
Goodwill	7.95M	83.03M
Debt to Capitalization	0.14	0.22
Debt to Assets	0.26	0.13
Current Ratio	1.93	3.12
Quick Ratio	0.84	2.77

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.00	0.06
R&D to Revenue		0.19
SG&A to Revenue		0.17